title: Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases.
abstract: OBJECTIVE
  It is unknown why some patients with biochemical evidence of primary aldosteronism (PA) do not develop hypertension. We aimed to compare clinical and biochemical characteristics of normotensive and hypertensive patients with PA.
  
  
  METHODS
  Retrospective comparison of 10 normotensive and 168 hypertensive patients with PA for office or ambulatory blood pressure, serum potassium, plasma aldosterone and renin concentrations; the aldosterone:renin ratio, and tumour size. Comparison of initial hormonal pattern and drop in blood pressure following adrenalectomy in five normotensive and nine hypertensive patients matched for age, sex and body mass index.
  
  
  RESULTS
  The 10 normotensive patients were women and presented with hypokalemia or an adrenal mass. Age, plasma aldosterone and renin concentrations were similar in normotensive and hypertensive cases, but kalemia and body mass index were significantly lower in the normotensive patients. Mean tumour diameter was larger in the normotensive patients than in the hypertensive matched patients with an adenoma (P < 0.01). In normotensive patients, diastolic blood pressure and upright aldosterone correlated negatively with kalemia. Blood pressure was lowered similarly after adrenalectomy in five normotensive PA patients and in their matched hypertensive counterparts. Aldosterone synthase expression was detected in four out of five adrenal tumours.
  
  
  CONCLUSIONS
  Blood pressure may be normal in patients with well-documented PA. The occurrence of hypokalemia, despite a normal blood pressure profile, suggests that protective mechanisms against hypertension are present in normotensive patients.
authors.affiliation: Département d'Hypertension, AP-HP, Hôpital Européen Georges Pompidou, Paris, France.
authors.forename: Virginie
authors.initials: V
authors.lastname: Médeau
authors.forename: François
authors.initials: F
authors.lastname: Moreau
authors.forename: Ludovic
authors.initials: L
authors.lastname: Trinquart
authors.forename: Maud
authors.initials: M
authors.lastname: Clemessy
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Wémeau
authors.forename: Marie Christine
authors.initials: MC
authors.lastname: Vantyghem
authors.forename: Pierre-François
authors.initials: PF
authors.lastname: Plouin
authors.forename: Yves
authors.initials: Y
authors.lastname: Reznik
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000150:complications / Q000235:genetics / Q000378:metabolism; D000315:Adrenalectomy; D018246:Adrenocortical Adenoma / Q000150:complications / Q000235:genetics / Q000378:metabolism; D000328:Adult; D015415:Biomarkers / Q000032:analysis* / Q000378:metabolism; D001794:Blood Pressure / Q000502:physiology*; D016022:Case-Control Studies; D019405:Cytochrome P-450 CYP11B2 / Q000235:genetics / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006929:Hyperaldosteronism / Q000150:complications / Q000209:etiology / Q000235:genetics / Q000503:physiopathology*; D006973:Hypertension / Q000150:complications* / Q000235:genetics / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013252:Steroid 11-beta-Hydroxylase / Q000235:genetics / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D019405:Cytochrome P-450 CYP11B2; D013252:Steroid 11-beta-Hydroxylase